Bank of America Securities: Reiterates Buy rating for INNOVENT BIO (01801) and HANSOH PHARMA (03692) with both Target Prices raised.

INNOVENT BIO (01801) recently reached a commercialization agreement with Eli Lilly and Co (LLY.US) for its non-covalent (reversible) BTK inhibitor "Jepalibri" in mainland China.

Zhitong FinanceDec 19 22:47 ET

Hansoh Pharmaceutical Units Sign Up to $2 Billion Licensing Deal for Weight Loss Drug Candidate

MT NewswiresDec 19 21:57 ET

The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 09:27 ET

Morgan Stanley: Maintains "Shareholding" rating on HANSOH PHARMA (03692) with a Target Price of 24 Hong Kong dollars.

HANSOH PHARMA announced the signing of a global exclusive licensing agreement with Merck, granting them global exclusive rights to develop, manufacture, and commercialize the preclinical oral small molecule GLP-1 receptor agonist HS-10535.

Zhitong FinanceDec 18 22:22 ET

Goldman Sachs: Initiates coverage on HANSOH PHARMA (03692) with a "Buy" rating and a Target Price of HKD 20.97.

Goldman Sachs believes that HANSOH PHARMA can jointly promote or independently commercialize this product in mainland China and Hong Kong and Macau.

Zhitong FinanceDec 18 20:48 ET

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

Simply Wall StDec 18 17:58 ET